KR20200065093A - 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법 - Google Patents

이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법 Download PDF

Info

Publication number
KR20200065093A
KR20200065093A KR1020207015341A KR20207015341A KR20200065093A KR 20200065093 A KR20200065093 A KR 20200065093A KR 1020207015341 A KR1020207015341 A KR 1020207015341A KR 20207015341 A KR20207015341 A KR 20207015341A KR 20200065093 A KR20200065093 A KR 20200065093A
Authority
KR
South Korea
Prior art keywords
itraconazole
administered
dose
auc
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207015341A
Other languages
English (en)
Korean (ko)
Inventor
스튜알트 제임스 머드쥐
데이빗 헤이스
스테판 루카스
Original Assignee
메인 파마 인터내셔널 프로프라이어터리 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902624A external-priority patent/AU2012902624A0/en
Application filed by 메인 파마 인터내셔널 프로프라이어터리 리미티드 filed Critical 메인 파마 인터내셔널 프로프라이어터리 리미티드
Publication of KR20200065093A publication Critical patent/KR20200065093A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207015341A 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법 Ceased KR20200065093A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902624 2012-06-21
AU2012902624A AU2012902624A0 (en) 2012-06-21 Itraconazole formulations and uses
PCT/US2013/047135 WO2013192566A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20157001531A Division KR20150043296A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010610A Division KR20210043721A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Publications (1)

Publication Number Publication Date
KR20200065093A true KR20200065093A (ko) 2020-06-08

Family

ID=49769445

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207015341A Ceased KR20200065093A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
KR1020217010610A Abandoned KR20210043721A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
KR20157001531A Ceased KR20150043296A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217010610A Abandoned KR20210043721A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
KR20157001531A Ceased KR20150043296A (ko) 2012-06-21 2013-06-21 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Country Status (11)

Country Link
US (7) US8921374B2 (https=)
EP (1) EP2863911A4 (https=)
JP (2) JP2015531749A (https=)
KR (3) KR20200065093A (https=)
CN (2) CN104507480A (https=)
AU (3) AU2013278001A1 (https=)
BR (1) BR112014031706A8 (https=)
CA (1) CA2876909C (https=)
HK (1) HK1207288A1 (https=)
MX (1) MX366829B (https=)
WO (1) WO2013192566A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
US11390613B2 (en) 2017-08-20 2022-07-19 University Of Connecticut Azole analogues and methods of use thereof
AU2019277362A1 (en) * 2018-05-30 2021-01-21 Mayne Pharma International Pty Ltd Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
CN115768779A (zh) * 2020-05-07 2023-03-07 上海偕怡医药科技有限公司 伊曲康唑前药及其用途
WO2023007514A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy's Laboratories Limited Improved oral bioavailable pharmaceutical compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
DE69730241T2 (de) 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
CA2317106C (en) 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
KR100529766B1 (ko) * 2003-09-09 2005-11-17 한미약품 주식회사 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
US20050058670A1 (en) 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
US8486456B2 (en) * 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20110262517A1 (en) * 2007-04-05 2011-10-27 The Johns Hopkins University Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
BR112014031706A8 (pt) 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol

Also Published As

Publication number Publication date
US20140005205A1 (en) 2014-01-02
MX366829B (es) 2019-07-25
HK1207288A1 (en) 2016-01-29
US20160030582A1 (en) 2016-02-04
JP2018162304A (ja) 2018-10-18
CA2876909C (en) 2022-08-16
CN104507480A (zh) 2015-04-08
EP2863911A1 (en) 2015-04-29
US10463740B2 (en) 2019-11-05
WO2013192566A1 (en) 2013-12-27
CA2876909A1 (en) 2013-12-27
US9272046B2 (en) 2016-03-01
JP6757367B2 (ja) 2020-09-16
AU2013278001A1 (en) 2015-01-22
US20190125879A1 (en) 2019-05-02
MX2015000179A (es) 2016-02-16
US20150099763A1 (en) 2015-04-09
US11638758B2 (en) 2023-05-02
KR20150043296A (ko) 2015-04-22
KR20210043721A (ko) 2021-04-21
US8921374B2 (en) 2014-12-30
US20210038728A1 (en) 2021-02-11
AU2018201298B2 (en) 2020-05-14
US20200138959A1 (en) 2020-05-07
EP2863911A4 (en) 2016-07-13
AU2018201298A1 (en) 2018-03-15
US9713642B2 (en) 2017-07-25
BR112014031706A8 (pt) 2021-10-19
AU2020217438A1 (en) 2020-09-03
US10806792B2 (en) 2020-10-20
US20170348421A1 (en) 2017-12-07
BR112014031706A2 (pt) 2017-06-27
JP2015531749A (ja) 2015-11-05
CN109674795A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
US11638758B2 (en) Itraconazole compositions and dosage forms, and methods of using the same
TWI871342B (zh) 非鎮靜之右美托咪啶(dexmedetomidine)治療方案
EP2678320B1 (en) Flumazenil complexes, compositions comprising same and uses thereof
AU2023233115A1 (en) Methods of treating eosinophilic esophagitis
EP3323413B1 (en) Pharmaceutical composition containing celecoxib and tramadol
HU227810B1 (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt
US9913839B2 (en) Dosing regimens for fast onset of antidepressant effect
US20240041765A1 (en) Oral liquid suspension of pan-raf kinase inhibitor
WO2023007514A1 (en) Improved oral bioavailable pharmaceutical compositions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200528

Application number text: 1020157001531

Filing date: 20150120

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200807

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210210

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210809

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210210

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200807

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I